 Jon Matsumura
Concepts (431)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Blood Vessel Prosthesis Implantation | 74 | 2023 | 181 | 14.100 |
Why?
| | Aortic Aneurysm, Abdominal | 57 | 2023 | 118 | 10.350 |
Why?
| | Blood Vessel Prosthesis | 48 | 2022 | 115 | 8.740 |
Why?
| | Endovascular Procedures | 37 | 2023 | 273 | 8.590 |
Why?
| | Stents | 56 | 2022 | 457 | 7.600 |
Why?
| | Aortic Aneurysm, Thoracic | 28 | 2022 | 121 | 7.540 |
Why?
| | Aorta, Thoracic | 23 | 2022 | 248 | 4.720 |
Why?
| | Carotid Stenosis | 20 | 2023 | 75 | 3.660 |
Why?
| | Vascular Surgical Procedures | 19 | 2018 | 262 | 2.920 |
Why?
| | Iliac Aneurysm | 7 | 2023 | 13 | 2.660 |
Why?
| | Tomography, X-Ray Computed | 32 | 2021 | 2433 | 2.270 |
Why?
| | Vascular System Injuries | 5 | 2018 | 69 | 2.220 |
Why?
| | Endarterectomy, Carotid | 12 | 2021 | 41 | 2.150 |
Why?
| | Prosthesis Design | 30 | 2022 | 285 | 2.080 |
Why?
| | Aortography | 14 | 2021 | 52 | 2.060 |
Why?
| | Aortic Diseases | 8 | 2019 | 94 | 2.020 |
Why?
| | Treatment Outcome | 78 | 2023 | 9311 | 1.880 |
Why?
| | Angioplasty | 10 | 2017 | 39 | 1.850 |
Why?
| | Iliac Artery | 9 | 2023 | 44 | 1.830 |
Why?
| | Aortic Rupture | 12 | 2022 | 26 | 1.740 |
Why?
| | Angioplasty, Balloon | 9 | 2013 | 88 | 1.580 |
Why?
| | Stroke | 15 | 2023 | 1043 | 1.460 |
Why?
| | Time Factors | 43 | 2023 | 6362 | 1.390 |
Why?
| | Aortic Aneurysm | 7 | 2017 | 51 | 1.370 |
Why?
| | Aged | 85 | 2023 | 19557 | 1.270 |
Why?
| | Aged, 80 and over | 43 | 2022 | 6533 | 1.250 |
Why?
| | Sarcopenia | 2 | 2019 | 72 | 1.240 |
Why?
| | Computed Tomography Angiography | 5 | 2021 | 81 | 1.120 |
Why?
| | Prosthesis Failure | 10 | 2017 | 120 | 1.090 |
Why?
| | Subclavian Artery | 6 | 2022 | 31 | 1.040 |
Why?
| | Vascular Patency | 12 | 2021 | 98 | 1.000 |
Why?
| | Postoperative Complications | 27 | 2022 | 2230 | 1.000 |
Why?
| | Humans | 155 | 2023 | 118066 | 0.920 |
Why?
| | Middle Aged | 64 | 2022 | 27434 | 0.910 |
Why?
| | Myocardial Infarction | 3 | 2021 | 966 | 0.880 |
Why?
| | Risk Factors | 31 | 2023 | 8950 | 0.870 |
Why?
| | Vena Cava Filters | 5 | 2023 | 50 | 0.870 |
Why?
| | Femoral Artery | 4 | 2013 | 176 | 0.860 |
Why?
| | Male | 99 | 2023 | 57376 | 0.850 |
Why?
| | Prospective Studies | 29 | 2023 | 6443 | 0.830 |
Why?
| | Aorta, Abdominal | 7 | 2020 | 40 | 0.820 |
Why?
| | Ulcer | 3 | 2014 | 28 | 0.800 |
Why?
| | Female | 94 | 2022 | 61147 | 0.770 |
Why?
| | Foreign-Body Migration | 3 | 2017 | 37 | 0.730 |
Why?
| | Ischemia | 5 | 2018 | 370 | 0.710 |
Why?
| | United States | 31 | 2022 | 12477 | 0.700 |
Why?
| | Peripheral Arterial Disease | 2 | 2018 | 378 | 0.700 |
Why?
| | Frailty | 2 | 2019 | 116 | 0.700 |
Why?
| | Predictive Value of Tests | 9 | 2021 | 1850 | 0.690 |
Why?
| | Psoas Muscles | 1 | 2018 | 6 | 0.680 |
Why?
| | Reoperation | 12 | 2020 | 554 | 0.680 |
Why?
| | Risk Assessment | 17 | 2021 | 3041 | 0.680 |
Why?
| | Popliteal Artery | 4 | 2015 | 59 | 0.670 |
Why?
| | Marfan Syndrome | 1 | 2019 | 41 | 0.670 |
Why?
| | Retrospective Studies | 39 | 2023 | 12922 | 0.650 |
Why?
| | Body Composition | 2 | 2019 | 644 | 0.630 |
Why?
| | Societies, Medical | 5 | 2020 | 700 | 0.620 |
Why?
| | Population Surveillance | 1 | 2021 | 413 | 0.620 |
Why?
| | Endoleak | 7 | 2022 | 13 | 0.600 |
Why?
| | Chlorhexidine | 1 | 2017 | 22 | 0.590 |
Why?
| | Decontamination | 1 | 2017 | 22 | 0.590 |
Why?
| | Anti-Infective Agents, Local | 1 | 2017 | 42 | 0.580 |
Why?
| | Elective Surgical Procedures | 8 | 2020 | 159 | 0.580 |
Why?
| | Health Care Costs | 3 | 2014 | 390 | 0.560 |
Why?
| | Embolization, Therapeutic | 2 | 2022 | 192 | 0.540 |
Why?
| | Infection Control | 1 | 2017 | 135 | 0.530 |
Why?
| | Radiography, Interventional | 5 | 2019 | 113 | 0.520 |
Why?
| | Education, Medical, Continuing | 2 | 2014 | 124 | 0.500 |
Why?
| | Lower Extremity | 1 | 2018 | 334 | 0.490 |
Why?
| | Surgical Wound Infection | 1 | 2017 | 251 | 0.490 |
Why?
| | Patient Readmission | 3 | 2014 | 630 | 0.480 |
Why?
| | Program Development | 2 | 2014 | 353 | 0.470 |
Why?
| | Alloys | 2 | 2013 | 31 | 0.470 |
Why?
| | Follow-Up Studies | 24 | 2020 | 4571 | 0.450 |
Why?
| | Vascular Diseases | 2 | 2014 | 241 | 0.450 |
Why?
| | Thoracic Injuries | 2 | 2013 | 62 | 0.450 |
Why?
| | Kaplan-Meier Estimate | 10 | 2019 | 837 | 0.440 |
Why?
| | Health Expenditures | 1 | 2014 | 174 | 0.440 |
Why?
| | Carotid Artery Diseases | 3 | 2005 | 58 | 0.440 |
Why?
| | Congresses as Topic | 1 | 2014 | 203 | 0.430 |
Why?
| | Skin | 1 | 2017 | 658 | 0.420 |
Why?
| | Patient Selection | 7 | 2021 | 669 | 0.420 |
Why?
| | Embolic Protection Devices | 1 | 2012 | 10 | 0.410 |
Why?
| | Minimally Invasive Surgical Procedures | 7 | 2009 | 158 | 0.400 |
Why?
| | Pulmonary Embolism | 2 | 2005 | 182 | 0.390 |
Why?
| | Arterial Occlusive Diseases | 3 | 2008 | 74 | 0.390 |
Why?
| | Thromboembolism | 1 | 2012 | 99 | 0.380 |
Why?
| | Intracranial Embolism | 1 | 2010 | 27 | 0.370 |
Why?
| | Ultrasonography, Interventional | 3 | 2001 | 155 | 0.370 |
Why?
| | Muscle, Skeletal | 1 | 2019 | 1515 | 0.360 |
Why?
| | Filtration | 1 | 2010 | 62 | 0.360 |
Why?
| | Peripheral Vascular Diseases | 2 | 2004 | 98 | 0.360 |
Why?
| | Adult | 34 | 2022 | 31230 | 0.350 |
Why?
| | Wounds, Nonpenetrating | 5 | 2021 | 279 | 0.350 |
Why?
| | Constriction, Pathologic | 6 | 2023 | 204 | 0.340 |
Why?
| | Chi-Square Distribution | 5 | 2014 | 523 | 0.330 |
Why?
| | Thrombosis | 4 | 2018 | 301 | 0.330 |
Why?
| | Radiography | 7 | 2012 | 860 | 0.330 |
Why?
| | Survival Rate | 10 | 2016 | 1714 | 0.320 |
Why?
| | Doxycycline | 2 | 2020 | 59 | 0.320 |
Why?
| | Regional Blood Flow | 4 | 2018 | 416 | 0.320 |
Why?
| | Ultrasonography, Doppler, Duplex | 9 | 2017 | 39 | 0.320 |
Why?
| | Iliac Vein | 2 | 2006 | 9 | 0.320 |
Why?
| | Venous Thrombosis | 4 | 2005 | 145 | 0.310 |
Why?
| | Paraparesis | 2 | 2008 | 6 | 0.300 |
Why?
| | Graft Occlusion, Vascular | 4 | 2018 | 35 | 0.290 |
Why?
| | Spinal Cord Ischemia | 2 | 2010 | 78 | 0.290 |
Why?
| | Hospitals, University | 1 | 2007 | 171 | 0.290 |
Why?
| | Hospital Mortality | 4 | 2020 | 811 | 0.280 |
Why?
| | Ankle Brachial Index | 2 | 2018 | 30 | 0.270 |
Why?
| | Health Status | 3 | 2019 | 723 | 0.270 |
Why?
| | Epidemiologic Research Design | 1 | 2005 | 28 | 0.270 |
Why?
| | Retreatment | 2 | 2021 | 71 | 0.250 |
Why?
| | Erectile Dysfunction | 2 | 2023 | 37 | 0.250 |
Why?
| | Clinical Trials as Topic | 4 | 2019 | 960 | 0.240 |
Why?
| | Length of Stay | 5 | 2020 | 1027 | 0.240 |
Why?
| | Disease Progression | 5 | 2021 | 2476 | 0.240 |
Why?
| | Multicenter Studies as Topic | 3 | 2014 | 251 | 0.240 |
Why?
| | Severity of Illness Index | 8 | 2017 | 2652 | 0.230 |
Why?
| | Femoral Vein | 3 | 2001 | 29 | 0.230 |
Why?
| | Preoperative Care | 3 | 2017 | 332 | 0.230 |
Why?
| | Catheterization, Peripheral | 3 | 2009 | 106 | 0.220 |
Why?
| | Comorbidity | 7 | 2019 | 1520 | 0.210 |
Why?
| | Paraplegia | 4 | 2011 | 60 | 0.210 |
Why?
| | Carotid Artery, Internal | 5 | 2008 | 34 | 0.210 |
Why?
| | Prosthesis Implantation | 2 | 2002 | 141 | 0.200 |
Why?
| | Aftercare | 2 | 2020 | 194 | 0.200 |
Why?
| | Clinical Competence | 6 | 2019 | 942 | 0.200 |
Why?
| | Odds Ratio | 3 | 2014 | 992 | 0.200 |
Why?
| | Registries | 2 | 2019 | 1806 | 0.200 |
Why?
| | Equipment Design | 5 | 2011 | 517 | 0.190 |
Why?
| | Reproducibility of Results | 3 | 2018 | 2855 | 0.190 |
Why?
| | Eligibility Determination | 1 | 2021 | 55 | 0.190 |
Why?
| | Patients' Rooms | 1 | 2000 | 13 | 0.190 |
Why?
| | Logistic Models | 4 | 2015 | 1894 | 0.190 |
Why?
| | Collateral Circulation | 2 | 2010 | 19 | 0.180 |
Why?
| | Cause of Death | 4 | 2019 | 379 | 0.180 |
Why?
| | Abdominal Oblique Muscles | 1 | 2019 | 2 | 0.180 |
Why?
| | Intercostal Muscles | 1 | 2019 | 4 | 0.180 |
Why?
| | Thoracic Outlet Syndrome | 2 | 1997 | 12 | 0.180 |
Why?
| | Rectus Abdominis | 1 | 2019 | 12 | 0.180 |
Why?
| | Superficial Back Muscles | 1 | 2019 | 14 | 0.180 |
Why?
| | Oleic Acids | 1 | 1999 | 13 | 0.180 |
Why?
| | Credentialing | 1 | 2019 | 12 | 0.180 |
Why?
| | Spinal Fusion | 1 | 2022 | 225 | 0.180 |
Why?
| | Feasibility Studies | 6 | 2021 | 747 | 0.170 |
Why?
| | Cost-Benefit Analysis | 2 | 2020 | 551 | 0.170 |
Why?
| | Specialties, Surgical | 1 | 2020 | 76 | 0.170 |
Why?
| | Aneurysm, Ruptured | 2 | 2013 | 38 | 0.170 |
Why?
| | Double-Blind Method | 2 | 2021 | 1679 | 0.170 |
Why?
| | Observer Variation | 2 | 2018 | 303 | 0.170 |
Why?
| | Frail Elderly | 1 | 2019 | 105 | 0.170 |
Why?
| | Phosphatidylcholines | 1 | 1999 | 131 | 0.170 |
Why?
| | Anti-Bacterial Agents | 2 | 2020 | 1513 | 0.160 |
Why?
| | Surgeons | 1 | 2022 | 242 | 0.160 |
Why?
| | Curriculum | 1 | 2005 | 894 | 0.160 |
Why?
| | Disease-Free Survival | 3 | 2017 | 648 | 0.160 |
Why?
| | Gene Transfer Techniques | 1 | 1999 | 153 | 0.160 |
Why?
| | Electronic Mail | 1 | 2018 | 55 | 0.160 |
Why?
| | Protease Inhibitors | 1 | 2019 | 101 | 0.160 |
Why?
| | Neck Muscles | 1 | 1997 | 12 | 0.160 |
Why?
| | Limb Salvage | 1 | 2018 | 52 | 0.160 |
Why?
| | Critical Illness | 3 | 2018 | 662 | 0.150 |
Why?
| | Ribs | 1 | 1997 | 32 | 0.150 |
Why?
| | Clavicle | 1 | 1997 | 30 | 0.150 |
Why?
| | Anatomic Landmarks | 1 | 2017 | 28 | 0.150 |
Why?
| | Blood Vessels | 1 | 1999 | 187 | 0.150 |
Why?
| | Administration, Cutaneous | 1 | 2017 | 118 | 0.150 |
Why?
| | Axillary Artery | 1 | 1996 | 13 | 0.140 |
Why?
| | Bile Pigments | 1 | 1996 | 1 | 0.140 |
Why?
| | Cholagogues and Choleretics | 1 | 1996 | 10 | 0.140 |
Why?
| | Bile | 1 | 1996 | 31 | 0.140 |
Why?
| | Cholelithiasis | 1 | 1996 | 30 | 0.140 |
Why?
| | Incidence | 7 | 2016 | 2413 | 0.140 |
Why?
| | Quality Assurance, Health Care | 2 | 2019 | 323 | 0.140 |
Why?
| | Analysis of Variance | 2 | 2016 | 1285 | 0.130 |
Why?
| | United States Food and Drug Administration | 2 | 2009 | 174 | 0.130 |
Why?
| | Antihypertensive Agents | 1 | 2019 | 436 | 0.130 |
Why?
| | Anti-Inflammatory Agents | 1 | 2019 | 467 | 0.130 |
Why?
| | Antioxidants | 1 | 2019 | 562 | 0.130 |
Why?
| | Survival Analysis | 6 | 2016 | 1261 | 0.120 |
Why?
| | Spinal Injuries | 1 | 1995 | 51 | 0.120 |
Why?
| | Chicago | 3 | 2011 | 45 | 0.120 |
Why?
| | Evidence-Based Medicine | 4 | 2017 | 689 | 0.120 |
Why?
| | Prosthesis-Related Infections | 2 | 2008 | 74 | 0.120 |
Why?
| | Intermittent Claudication | 1 | 2015 | 110 | 0.120 |
Why?
| | Physician-Patient Relations | 1 | 2018 | 481 | 0.120 |
Why?
| | Wisconsin | 1 | 2013 | 91 | 0.120 |
Why?
| | Hospital Costs | 1 | 2014 | 110 | 0.120 |
Why?
| | Asymptomatic Diseases | 3 | 2019 | 81 | 0.120 |
Why?
| | Imaging, Three-Dimensional | 2 | 2016 | 500 | 0.120 |
Why?
| | Clinical Decision-Making | 3 | 2021 | 276 | 0.120 |
Why?
| | Taurocholic Acid | 1 | 1993 | 33 | 0.110 |
Why?
| | Gastrointestinal Diseases | 1 | 1995 | 186 | 0.110 |
Why?
| | Hypertension | 2 | 2021 | 1198 | 0.110 |
Why?
| | Parenteral Nutrition, Total | 1 | 1993 | 39 | 0.110 |
Why?
| | Diabetes Mellitus | 1 | 2021 | 939 | 0.110 |
Why?
| | Tertiary Care Centers | 1 | 2013 | 117 | 0.110 |
Why?
| | Postoperative Care | 1 | 2014 | 237 | 0.110 |
Why?
| | Aneurysm | 2 | 2003 | 32 | 0.110 |
Why?
| | Intestinal Absorption | 1 | 1993 | 104 | 0.110 |
Why?
| | Ileum | 1 | 1993 | 100 | 0.110 |
Why?
| | Endothelium, Vascular | 1 | 1999 | 889 | 0.110 |
Why?
| | Communication | 1 | 2018 | 750 | 0.110 |
Why?
| | Intraoperative Complications | 3 | 2019 | 133 | 0.110 |
Why?
| | Leg | 3 | 1999 | 234 | 0.110 |
Why?
| | Europe | 1 | 2013 | 354 | 0.110 |
Why?
| | Device Approval | 2 | 2009 | 21 | 0.100 |
Why?
| | Catheters | 1 | 2011 | 61 | 0.100 |
Why?
| | Permeability | 2 | 2009 | 154 | 0.100 |
Why?
| | Electronic Health Records | 1 | 2018 | 809 | 0.100 |
Why?
| | Exercise Tolerance | 1 | 2013 | 234 | 0.100 |
Why?
| | Residence Characteristics | 1 | 2013 | 297 | 0.100 |
Why?
| | Proportional Hazards Models | 3 | 2009 | 1123 | 0.100 |
Why?
| | Viscera | 1 | 2011 | 16 | 0.100 |
Why?
| | Netherlands | 2 | 2020 | 62 | 0.100 |
Why?
| | Bayes Theorem | 2 | 2023 | 342 | 0.100 |
Why?
| | Cardiovascular Diseases | 1 | 2022 | 1795 | 0.100 |
Why?
| | United States Department of Veterans Affairs | 1 | 2014 | 556 | 0.100 |
Why?
| | Vertebrobasilar Insufficiency | 1 | 2010 | 7 | 0.100 |
Why?
| | Ambulatory Care | 1 | 2014 | 481 | 0.090 |
Why?
| | Aneurysm, False | 1 | 2011 | 46 | 0.090 |
Why?
| | Longitudinal Studies | 1 | 2017 | 2487 | 0.090 |
Why?
| | Anesthesiology | 1 | 1990 | 39 | 0.090 |
Why?
| | Databases as Topic | 1 | 2010 | 65 | 0.090 |
Why?
| | Research Design | 3 | 2009 | 960 | 0.090 |
Why?
| | Exercise Test | 1 | 2013 | 552 | 0.090 |
Why?
| | Telemedicine | 1 | 2018 | 663 | 0.090 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2009 | 26 | 0.090 |
Why?
| | Multivariate Analysis | 1 | 2013 | 1468 | 0.090 |
Why?
| | Hospitals, Urban | 1 | 2010 | 129 | 0.090 |
Why?
| | Ischemic Attack, Transient | 2 | 2009 | 62 | 0.090 |
Why?
| | Socioeconomic Factors | 1 | 2013 | 1121 | 0.090 |
Why?
| | General Surgery | 2 | 2014 | 136 | 0.090 |
Why?
| | Dilatation, Pathologic | 2 | 1999 | 56 | 0.090 |
Why?
| | Porosity | 1 | 2009 | 93 | 0.080 |
Why?
| | Benchmarking | 1 | 2010 | 172 | 0.080 |
Why?
| | Extremities | 1 | 2009 | 112 | 0.080 |
Why?
| | Aorta | 2 | 2022 | 364 | 0.080 |
Why?
| | Rupture | 1 | 2009 | 105 | 0.080 |
Why?
| | Carotid Arteries | 1 | 2010 | 184 | 0.080 |
Why?
| | Age Factors | 2 | 2019 | 2991 | 0.080 |
Why?
| | Coronary Artery Bypass | 2 | 2000 | 210 | 0.080 |
Why?
| | Young Adult | 4 | 2021 | 10707 | 0.080 |
Why?
| | Ultrasonography | 4 | 2014 | 714 | 0.080 |
Why?
| | Treatment Failure | 2 | 2020 | 340 | 0.080 |
Why?
| | Patient Discharge | 1 | 2013 | 791 | 0.080 |
Why?
| | Carotid Artery Thrombosis | 1 | 2007 | 8 | 0.070 |
Why?
| | Organ Size | 2 | 2020 | 460 | 0.070 |
Why?
| | Equipment Safety | 2 | 2009 | 38 | 0.070 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2004 | 705 | 0.070 |
Why?
| | Delivery of Health Care | 1 | 2014 | 861 | 0.070 |
Why?
| | Brain Ischemia | 1 | 2010 | 309 | 0.070 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2014 | 2046 | 0.070 |
Why?
| | Arm | 2 | 1997 | 106 | 0.070 |
Why?
| | Stainless Steel | 1 | 2006 | 21 | 0.070 |
Why?
| | Calcinosis | 1 | 2009 | 283 | 0.070 |
Why?
| | Angiography | 3 | 2017 | 185 | 0.070 |
Why?
| | Polyesters | 1 | 2006 | 65 | 0.070 |
Why?
| | Prostheses and Implants | 1 | 2007 | 142 | 0.070 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2005 | 57 | 0.070 |
Why?
| | Recurrence | 3 | 2017 | 969 | 0.070 |
Why?
| | Hematoma | 1 | 2005 | 51 | 0.070 |
Why?
| | Vena Cava, Inferior | 2 | 2023 | 55 | 0.070 |
Why?
| | Renal Veins | 1 | 2004 | 12 | 0.060 |
Why?
| | Mesenteric Artery, Superior | 1 | 2004 | 12 | 0.060 |
Why?
| | Health Status Indicators | 1 | 2005 | 153 | 0.060 |
Why?
| | United Kingdom | 2 | 2003 | 234 | 0.060 |
Why?
| | Hernia, Ventral | 1 | 2004 | 19 | 0.060 |
Why?
| | Leadership | 1 | 2007 | 310 | 0.060 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2021 | 1237 | 0.060 |
Why?
| | Fluoroscopy | 2 | 2001 | 144 | 0.060 |
Why?
| | Nephrectomy | 1 | 2004 | 162 | 0.060 |
Why?
| | Delphi Technique | 1 | 2023 | 164 | 0.060 |
Why?
| | Data Collection | 1 | 2006 | 649 | 0.050 |
Why?
| | Perfusion | 1 | 2023 | 152 | 0.050 |
Why?
| | Cerebrovascular Disorders | 2 | 2000 | 85 | 0.050 |
Why?
| | Lumbosacral Region | 1 | 2022 | 50 | 0.050 |
Why?
| | Head and Neck Neoplasms | 1 | 2007 | 469 | 0.050 |
Why?
| | Illinois | 3 | 2008 | 38 | 0.050 |
Why?
| | Animals | 4 | 2019 | 33107 | 0.050 |
Why?
| | Substance-Related Disorders | 1 | 1990 | 966 | 0.050 |
Why?
| | Learning Curve | 1 | 2022 | 67 | 0.050 |
Why?
| | Quality of Health Care | 1 | 2007 | 586 | 0.050 |
Why?
| | Device Removal | 1 | 2023 | 127 | 0.050 |
Why?
| | Time | 1 | 2002 | 77 | 0.050 |
Why?
| | England | 1 | 2001 | 69 | 0.050 |
Why?
| | Maxillary Sinus Neoplasms | 1 | 2001 | 8 | 0.050 |
Why?
| | Consensus | 1 | 2023 | 531 | 0.050 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2021 | 83 | 0.050 |
Why?
| | Biomedical Research | 1 | 2007 | 601 | 0.050 |
Why?
| | Internship and Residency | 1 | 1990 | 1002 | 0.050 |
Why?
| | Costs and Cost Analysis | 1 | 2001 | 201 | 0.050 |
Why?
| | Peritoneum | 1 | 2000 | 36 | 0.050 |
Why?
| | Cerebral Angiography | 1 | 2000 | 116 | 0.050 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 193 | 0.050 |
Why?
| | Practice Guidelines as Topic | 4 | 2010 | 1434 | 0.050 |
Why?
| | Quality of Life | 4 | 2012 | 2360 | 0.050 |
Why?
| | Troponin T | 1 | 2000 | 50 | 0.040 |
Why?
| | Radiotherapy | 1 | 2001 | 187 | 0.040 |
Why?
| | Cation Exchange Resins | 1 | 1999 | 7 | 0.040 |
Why?
| | Point-of-Care Systems | 1 | 2001 | 146 | 0.040 |
Why?
| | Spermine | 1 | 1999 | 28 | 0.040 |
Why?
| | Intracranial Aneurysm | 1 | 2000 | 99 | 0.040 |
Why?
| | Injury Severity Score | 2 | 2013 | 500 | 0.040 |
Why?
| | Arteriovenous Shunt, Surgical | 1 | 1999 | 16 | 0.040 |
Why?
| | Monitoring, Intraoperative | 1 | 1999 | 43 | 0.040 |
Why?
| | Echocardiography, Transesophageal | 1 | 2000 | 89 | 0.040 |
Why?
| | Luciferases | 1 | 1999 | 142 | 0.040 |
Why?
| | Emergency Treatment | 1 | 2020 | 110 | 0.040 |
Why?
| | Practice Patterns, Physicians' | 3 | 2019 | 1195 | 0.040 |
Why?
| | Veins | 1 | 1999 | 59 | 0.040 |
Why?
| | Genes, Reporter | 1 | 1999 | 268 | 0.040 |
Why?
| | Glycine | 1 | 1999 | 162 | 0.040 |
Why?
| | Postoperative Period | 1 | 1999 | 307 | 0.040 |
Why?
| | Drug Carriers | 1 | 1999 | 119 | 0.040 |
Why?
| | Plasmids | 1 | 1999 | 353 | 0.040 |
Why?
| | Radiography, Abdominal | 1 | 1998 | 32 | 0.040 |
Why?
| | Myocardial Contraction | 1 | 2000 | 338 | 0.040 |
Why?
| | Arteriosclerosis | 1 | 1998 | 88 | 0.040 |
Why?
| | Surgical Flaps | 1 | 1999 | 118 | 0.040 |
Why?
| | Administration, Oral | 1 | 2020 | 751 | 0.040 |
Why?
| | Subclavian Vein | 1 | 1997 | 22 | 0.040 |
Why?
| | Anastomosis, Surgical | 1 | 1998 | 146 | 0.040 |
Why?
| | Multiple Trauma | 2 | 2010 | 88 | 0.040 |
Why?
| | Veterans | 1 | 2008 | 1214 | 0.040 |
Why?
| | Blood Proteins | 1 | 1999 | 240 | 0.040 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 1997 | 28 | 0.040 |
Why?
| | Intraoperative Care | 1 | 1997 | 38 | 0.040 |
Why?
| | Retroperitoneal Neoplasms | 1 | 1997 | 23 | 0.040 |
Why?
| | Transfection | 1 | 1999 | 886 | 0.040 |
Why?
| | Hemodynamics | 2 | 2000 | 1002 | 0.040 |
Why?
| | Acute Disease | 2 | 2011 | 933 | 0.040 |
Why?
| | Prognosis | 2 | 2015 | 3421 | 0.040 |
Why?
| | Cholic Acids | 1 | 1996 | 17 | 0.030 |
Why?
| | Lipid Metabolism | 1 | 1999 | 473 | 0.030 |
Why?
| | Atherosclerosis | 1 | 2019 | 344 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 1999 | 1301 | 0.030 |
Why?
| | Wound Healing | 1 | 1998 | 271 | 0.030 |
Why?
| | Lipids | 1 | 1999 | 591 | 0.030 |
Why?
| | Taurine | 1 | 1996 | 46 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2001 | 891 | 0.030 |
Why?
| | Movement | 1 | 1997 | 248 | 0.030 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2001 | 610 | 0.030 |
Why?
| | Sarcoma | 1 | 1997 | 137 | 0.030 |
Why?
| | Contrast Media | 1 | 1998 | 373 | 0.030 |
Why?
| | Prevalence | 1 | 2001 | 2321 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1999 | 1928 | 0.030 |
Why?
| | Dogs | 1 | 1996 | 367 | 0.030 |
Why?
| | Bile Acids and Salts | 1 | 1996 | 179 | 0.030 |
Why?
| | Databases, Factual | 1 | 2019 | 1189 | 0.030 |
Why?
| | Myocardium | 1 | 2000 | 965 | 0.030 |
Why?
| | Respiratory Insufficiency | 1 | 1998 | 289 | 0.030 |
Why?
| | Mass Screening | 1 | 2001 | 1048 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 1999 | 1159 | 0.030 |
Why?
| | Gene Expression | 1 | 1999 | 1480 | 0.030 |
Why?
| | Cohort Studies | 3 | 2012 | 5072 | 0.030 |
Why?
| | Accidents, Traffic | 2 | 2005 | 176 | 0.030 |
Why?
| | Swine, Miniature | 1 | 1993 | 70 | 0.030 |
Why?
| | Blood Flow Velocity | 2 | 2005 | 327 | 0.030 |
Why?
| | Least-Squares Analysis | 1 | 2012 | 72 | 0.030 |
Why?
| | DNA | 1 | 1999 | 1381 | 0.030 |
Why?
| | Random Allocation | 1 | 1993 | 344 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 1993 | 379 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2022 | 4518 | 0.030 |
Why?
| | Case-Control Studies | 2 | 2014 | 3142 | 0.030 |
Why?
| | Quality-Adjusted Life Years | 1 | 2012 | 103 | 0.030 |
Why?
| | Anticoagulants | 1 | 2016 | 554 | 0.030 |
Why?
| | Cells, Cultured | 1 | 1999 | 4042 | 0.020 |
Why?
| | Physician Impairment | 1 | 1990 | 6 | 0.020 |
Why?
| | Swine | 1 | 1993 | 719 | 0.020 |
Why?
| | Polytetrafluoroethylene | 2 | 2003 | 25 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 2 | 2003 | 3160 | 0.020 |
Why?
| | Blood Component Transfusion | 1 | 2010 | 69 | 0.020 |
Why?
| | Infant | 1 | 2023 | 8256 | 0.020 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2009 | 64 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2010 | 324 | 0.020 |
Why?
| | Probability | 1 | 2010 | 301 | 0.020 |
Why?
| | Medicare | 1 | 2014 | 666 | 0.020 |
Why?
| | Morbidity | 1 | 2009 | 293 | 0.020 |
Why?
| | Advisory Committees | 1 | 2009 | 212 | 0.020 |
Why?
| | Postoperative Hemorrhage | 1 | 2008 | 79 | 0.020 |
Why?
| | Suture Techniques | 1 | 2008 | 134 | 0.020 |
Why?
| | Regression Analysis | 1 | 2010 | 984 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2018 | 4682 | 0.020 |
Why?
| | Catheterization | 1 | 2007 | 164 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 1996 | 3670 | 0.020 |
Why?
| | Guideline Adherence | 1 | 2010 | 519 | 0.020 |
Why?
| | Phenotype | 1 | 2014 | 2916 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2014 | 2238 | 0.020 |
Why?
| | Pyelonephritis, Xanthogranulomatous | 1 | 2004 | 3 | 0.020 |
Why?
| | Ligation | 1 | 2004 | 82 | 0.020 |
Why?
| | Thrombectomy | 1 | 2004 | 59 | 0.010 |
Why?
| | Escherichia coli Infections | 1 | 2004 | 105 | 0.010 |
Why?
| | Transplantation, Autologous | 1 | 2004 | 190 | 0.010 |
Why?
| | Hospitalization | 1 | 2012 | 1778 | 0.010 |
Why?
| | Adolescent | 2 | 2006 | 18342 | 0.010 |
Why?
| | Washington | 1 | 2003 | 141 | 0.010 |
Why?
| | Popliteal Vein | 1 | 2001 | 4 | 0.010 |
Why?
| | Chronic Disease | 1 | 2008 | 1634 | 0.010 |
Why?
| | Trismus | 1 | 2001 | 2 | 0.010 |
Why?
| | Hospital Charges | 1 | 2001 | 42 | 0.010 |
Why?
| | Child, Preschool | 1 | 1995 | 9442 | 0.010 |
Why?
| | Obesity, Morbid | 1 | 2004 | 197 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2005 | 1783 | 0.010 |
Why?
| | Cellulitis | 1 | 2001 | 47 | 0.010 |
Why?
| | Radiotherapy Dosage | 1 | 2001 | 245 | 0.010 |
Why?
| | Creatine Kinase | 1 | 2000 | 74 | 0.010 |
Why?
| | Eye Diseases | 1 | 2001 | 78 | 0.010 |
Why?
| | Necrosis | 1 | 2001 | 226 | 0.010 |
Why?
| | Anesthesia, General | 1 | 2000 | 48 | 0.010 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2001 | 358 | 0.010 |
Why?
| | Isoenzymes | 1 | 2000 | 296 | 0.010 |
Why?
| | Rectum | 1 | 2000 | 155 | 0.010 |
Why?
| | Cardiopulmonary Bypass | 1 | 2000 | 198 | 0.010 |
Why?
| | Myocardial Ischemia | 1 | 2000 | 251 | 0.010 |
Why?
| | Blindness | 1 | 1998 | 35 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 2001 | 1162 | 0.010 |
Why?
| | Drug Evaluation | 1 | 1997 | 81 | 0.010 |
Why?
| | Neoplasm Staging | 1 | 2001 | 1218 | 0.010 |
Why?
| | Electrocardiography | 1 | 2000 | 555 | 0.010 |
Why?
| | Decision Making | 1 | 2003 | 806 | 0.010 |
Why?
| | Diabetes Complications | 1 | 1998 | 218 | 0.010 |
Why?
| | Child | 1 | 1995 | 19029 | 0.010 |
Why?
| | Heparin | 1 | 1997 | 230 | 0.010 |
Why?
| | Algorithms | 1 | 2001 | 1520 | 0.010 |
Why?
| | Hemorrhage | 1 | 1998 | 606 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 1997 | 1376 | 0.010 |
Why?
| | Smoking | 1 | 1998 | 1469 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2000 | 4886 | 0.010 |
Why?
| | Mice | 1 | 2000 | 15425 | 0.000 |
Why?
|
|
Matsumura's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|